Get the Stockscreener App
17.76
1.99%
-0.36
After Hours:
17.86
0.10
+0.56%
Monte Rosa Therapeutics Inc stock is traded at $17.76, with a volume of 790.65K.
It is down -1.99% in the last 24 hours and down -2.15% over the past month.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
See More
Previous Close:
$18.12
Open:
$18.04
24h Volume:
790.65K
Relative Volume:
0.79
Market Cap:
$1.50B
Revenue:
$42.95M
Net Income/Loss:
$-130.01M
P/E Ratio:
-10.91
EPS:
-1.6278
Net Cash Flow:
$-19.66M
1W Performance:
+6.92%
1M Performance:
-2.15%
6M Performance:
-4.82%
1Y Performance:
+268.46%
1-Day Range:
$17.38
$18.50
1-Week Range:
$16.28
$19.00
52-Week Range:
$4.12
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
17.76 | 1.53B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN
Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by Alphabet Inc. - MarketBeat
Director at Monte Rosa (GLUE) awarded 25,800 stock options - Stock Titan
Monte Rosa Therapeutics (GLUE) director receives 25,800 stock options grant - Stock Titan
Monte Rosa Therapeutics (GLUE) director gets 25,800 options grant - Stock Titan
Monte Rosa Therapeutics (GLUE) grants director Jan Skvarka 25,800 options - Stock Titan
Monte Rosa Therapeutics (GLUE) director awarded 25,800 stock options - Stock Titan
Monte Rosa Therapeutics (GLUE) director granted 25,800 stock options - Stock Titan
Director at Monte Rosa (NASDAQ: GLUE) awarded 25,800 stock options - Stock Titan
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential - Seeking Alpha
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN
Monte Rosa Therapeutics (NASDAQ: GLUE) shareholders elect directors, ratify auditor - Stock Titan
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? - Investing.com
GLUE Technical Analysis & Stock Price Forecast - Intellectia AI
GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy - Insider Monkey
We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate - Moomoo
10 Best Growth Stocks Under $20 to Buy - Insider Monkey
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Monte Rosa (NASDAQ: GLUE) CEO sells 5,466 shares under Rule 10b5-1 plan - Stock Titan
Monte Rosa Therapeutics (GLUE) amends Form 144; RSU award and sales noted - Stock Titan
Monte Rosa (GLUE) insider Markus Warmuth reports multiple sales on Form 144 - Stock Titan
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares under 10b5-1 plan - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
Monte Rosa COO Jennifer Champoux sells $43,500 in stock By Investing.com - Investing.com Nigeria
Monte Rosa COO Jennifer Champoux sells $43,500 in stock - Investing.com India
Monte Rosa Therapeutics (NASDAQ: GLUE) COO exercises options and sells 2,175 shares - Stock Titan
GLUE (NASDAQ: GLUE) Form 144: proposed sale of 2,175 shares - Stock Titan
Monte Rosa (NASDAQ: GLUE) COO exercises options and sells 2,176 shares under plan - Stock Titan
Monte Rosa Therapeutics director sells $180,100 of Glue shares By Investing.com - Investing.com India
Monte Rosa Therapeutics director sells $180,100 of Glue shares - Investing.com UK
Monte Rosa Therapeutics (GLUE) director exercises options and sells 10K shares - Stock Titan
IDEA Pharma recognizes Monte Rosa Therapeutics for advancing MGD drug development - Traders Union
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Monte Rosa lines up TD Cowen and Jefferies investor talks - Stock Titan
Vanguard Group Inc. Has $50.91 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Monte Rosa Therapeutics (GLUE) — TCG/Chen Yu report 5.5% holding - Stock Titan
[SCHEDULE 13G/A] Monte Rosa Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
BVF Group (GLUE) entities report up to 5.09M shares, 6.3% total - Stock Titan
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
EX-99.1 - SEC.gov
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Monte Rosa Therapeutics to detail new molecular glue degrader research at Endpoints webinar - Traders Union
Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention - Yahoo Finance
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):